Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen CNBCLilly to launch multi-dose weight-loss drug device in US Yahoo FinanceLilly adds multidose Zepbound pens to self-pay menu after FDA nod Fierce PharmaDiabetes Dialogue: Launch of the Zepbound KwikPen HCPLive
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
